Mallinckrodt opens new €10m R&D offices, adding 40 new roles
US pharmaceutical firm Mallinckrodt has opened a new €10m research and development centre, creating 40 new jobs in the process.
The new premises, which is based in Blanchardstown in Dublin, will house the company's global device engineering.
The additional jobs will bring the firm's headcount up to 120 at the new site by the 2017. Mallinckrodt has now invested €85m into its Dublin site.
Chief executive Mark Trudeau said: “Today’s dedication and announcement reaffirms Ireland’s strategic importance to Mallinckrodt as we continue with our transition to become a high-growth, global specialty pharmaceutical business.
"We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio."
Social protection minister and local TD Leo Varadkar welcomed the new investment.
"This company is at the cutting edge of new and innovative treatments and the range of facilities being developed here is an exciting development. The Government has worked hard to create the right conditions for cutting edge Pharma and BioPharma companies to locate in Ireland and the provision of high quality jobs in this new Research and Development facility is very welcome."